First human trial of BI 765049 combo aims to fight hard-to-treat cancers
NCT ID NCT04752215
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants receive the drugs by infusion every three weeks for up to three years if they benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 765049 and ezabenlimab
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 67 participants, so it is primarily testing safety and dosing. It may not show strong anti-tumor effects, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida, 34232, United States
-
HealthONE
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806, United States
-
Mary Crowley Cancer Research Center
Dallas, Texas, 75230, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Norton Healthcare - Norton Cancer Institute - Louisville
Louisville, Kentucky, 40202, United States
-
Princess Margaret Cancer Centre
Toronto, M5G 1Z5, Canada
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Tennessee Oncology, PLLC-Nashville-52568
Nashville, Tennessee, 37203, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California Irvine
Orange, California, 92868, United States
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a cancer vaccine prime the body to better fight liver tumors?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?